- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- BG00011, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 21 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 262
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Obstructive Pulmonary, Idiopathic Pulmonary Fibrosis, Cystic Fibrosis, Bronchiectasis, Pulmonary Vascular Disease
- Interventions
- Placebo, EZ-2053, EZ-2053 5mg/kg
- Biological
- Lead sponsor
- Neovii Biotech
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 223 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 15
- States / cities
- Los Angeles, California • San Francisco, California • Stanford, California + 11 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Nintedanib, Pirfenidone
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 6
- States / cities
- Danbury, Connecticut • New Orleans, Louisiana • Minneapolis, Minnesota + 3 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Placebo Oral Tablet, GKT137831
- Other · Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • New Orleans, Louisiana • Ann Arbor, Michigan + 1 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Yoga
- Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Idiopathic Pulmonary Fibrosis, Cough
- Interventions
- Thalidomide, Placebo
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Nintedanib, Pirfenidone, Untreated Cohort
- Drug · Other
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 13,264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Plymouth, Pennsylvania
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- VAY736, Placebo, Standard of Care (SoC)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Aurora, Colorado • Miami, Florida + 4 more
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
- Interventions
- Not listed
- Lead sponsor
- Global Healthy Living Foundation
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 40,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2025
- U.S. locations
- 1
- States / cities
- Upper Nyack, New York
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Artesuante, Placebo capsules
- Drug · Other
- Lead sponsor
- Joseph C. Wu
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- PET/CT using PET ligands [F-18]FDG and [F-18]DPA-714
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD), Smoking, Smoking Cessation, Idiopathic Pulmonary Fibrosis (IPF), Rheumatoid Arthritis-Associated Interstitial Lung Disease, Scleroderma-Associated Interstitial Lung Disease (SSC-ILD)
- Interventions
- Not listed
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Pamrevlumab, Placebo, Sub-Study: Pirfenidone, Sub-Study: Nintedanib
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 23 more
- Conditions
- Pulmonary Fibrosis
- Interventions
- Placebo, CNTO 888 1 mg/kg, CNTO 888 5 mg/kg, CNTO 888 15 mg/kg
- Drug
- Lead sponsor
- Centocor, Inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Miami, Florida + 14 more
- Conditions
- Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
- Interventions
- Nerandomilast
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,666 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 58
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 46 more
- Conditions
- Pulmonary Fibrosis
- Interventions
- BMS-986278
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- Not listed
- Enrollment
- 2,380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Ocala, Florida • Philadelphia, Pennsylvania
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- PRM-151, placebo
- Biological · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 10
- States / cities
- San Francisco, California • Denver, Colorado • New Haven, Connecticut + 7 more
- Conditions
- Pulmonary Fibrosis
- Interventions
- BMS-986278 Placebo, BMS-986278
- Other · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 403 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more
- Conditions
- Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, Lung Disease
- Interventions
- Interferon gamma-1b
- Drug
- Lead sponsor
- InterMune
- Industry
- Eligibility
- Not listed
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Brisbane, California
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Nintedanib, Pulmonary rehabilitation program
- Drug · Other
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Loma Linda, California • Danbury, Connecticut + 16 more
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- BG00011, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 84 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 10
- States / cities
- San Francisco, California • Atlanta, Georgia • Kansas City, Kansas + 6 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- NAL ER, Placebo
- Drug
- Lead sponsor
- Trevi Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Fibrotic Interstitial Lung Disease, IPF and PPF, Lung Fibrosis Interstitial
- Interventions
- Spirometer, Oximeter, Scale, ePROs (electronic patient reported outcomes)
- Device · Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Interstitial Lung Disease
- Interventions
- Not listed
- Lead sponsor
- Pulmonary Care and Research Collaborative Limited
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts